APA (7th ed.) Citation

Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Waldron-Lynch, M., . . . Cortes, J. (2018). Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. European journal of cancer, 89, .

Chicago Style (17th ed.) Citation

Schneeweiss, Andreas, Stephen Chia, Tamas Hickish, Vernon Harvey, Alexandru Eniu, Maeve Waldron-Lynch, Jennifer Eng-Wong, Sarah Kirk, and Javier Cortes. "Long-term Efficacy Analysis of the Randomised, Phase II TRYPHAENA Cardiac Safety Study: Evaluating Pertuzumab and Trastuzumab Plus Standard Neoadjuvant Anthracycline-containing and Anthracycline-free Chemotherapy Regimens in Patients with HER2-positive Early Breast Cancer." European Journal of Cancer 89 (2018).

MLA (9th ed.) Citation

Schneeweiss, Andreas, et al. "Long-term Efficacy Analysis of the Randomised, Phase II TRYPHAENA Cardiac Safety Study: Evaluating Pertuzumab and Trastuzumab Plus Standard Neoadjuvant Anthracycline-containing and Anthracycline-free Chemotherapy Regimens in Patients with HER2-positive Early Breast Cancer." European Journal of Cancer, vol. 89, 2018.